Loading...
•
Sep 30, 2021
Jaguar Health Q3 2021 Earnings Report
Reported consolidated third quarter 2021 financial results.
Key Takeaways
Jaguar Health reported their Q3 2021 financial results, noting a 7.6% increase in Mytesi prescription volume compared to Q2 2021. The company is transitioning to a closed specialty pharmacy network by the end of 2021 as part of their market access strategy.
Mytesi prescription volume increased 7.6% in Q3 2021 over Q2 2021.
New Mytesi prescriptions increased 9.0% during the same period.
Mytesi net sales were approximately $0.6 million.
Mytesi gross sales were approximately $3.2 million.
Forward Guidance
Jaguar Health anticipates completing the transition to selling Mytesi through a closed specialty pharmacy network by the end of 2021 and expects to present Phase 2 HALT-D study results in December 2021.
Positive Outlook
- Transition to selling Mytesi through closed specialty pharmacy network expected to be complete by end of 2021.
- Phase 2 HALT-D study results presentation expected in December 2021.
- Launch of Canalevia™-CA1 for chemotherapy-induced diarrhea in dogs expected in late-December 2021.
- Transition to closed network of specialty pharmacies expected to result in a meaningful reduction in Mytesi distribution costs.
- Prepares U.S. commercial distribution network for future indication expansion of crofelemer
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...